Skip to main content

Table 2 Demographic information for patients who provided fibroblasts

From: C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice

 

Patient

Age/Sex

Histology

KL-6a (U/mL)

SP-Db (ng/mL)

FVC (L)

FEV1.0 (L)

TLC (L)

DLco (mL/min/mmHg)

With ILD

1

84/M

Sq

613

159

2.13

1.76

3.84

6.06

 

2

69/M

Sq

622

159

3.07

2.23

4.29

8.79

 

3

64/M

Ad

1129

321

2.77

2.27

4.25

12.0

 

4

79/M

Sq

599

62.4

2.85

2.14

4.36

9.75

 

5

77 M

Sq

658

103

2.71

2.21

4.32

12.9

Without ILD

1

81/F

Ad

NDc

NDc

1.95

1.45

3.24

9.84

 

2

79/F

Sq

NDc

NDc

2.27

1.76

3.98

12.8

 

3

81/M

Ad

NDc

NDc

3.17

2.18

5.39

16.3

  1. Definition of abbreviations:
  2. ILD interstitial lung disease, Sq squamous cell carcinoma, Ad adenocarcinoma, SP-D surfactant protein-D, FVC forced vital capacity, FEV1.0 forced expiratory volume 1.0 (sec), TLC total lung capacity, Dlco diffusing capacity of the lung carbon monoxide
  3. aNormal range of serum KL-6 is <500U/mL
  4. bNormal range of serum SP-D is <110 ng/mL
  5. cThe serum levels of KL-6 and SP-D in the patients without ILD were not examined
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us